Ben-Hur Tamir, Goldman Steven A
Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Ann N Y Acad Sci. 2008 Oct;1142:218-49. doi: 10.1196/annals.1444.014.
Recent advances in stem cell biology have raised expectations that both diseases of, and injuries to, the central nervous system may be ameliorated by cell transplantation. In particular, cell therapy has been studied for inducing efficient remyelination in disorders of myelin, including both the largely pediatric disorders of myelin formation and maintenance and the acquired demyelinations of both children and adults. Potential cell-based treatments of two major groups of disorders include both delivery of myelinogenic replacements and mobilization of residual oligodendrocyte progenitor cells as a means of stimulating endogenous repair; the choice of modality is then predicated upon the disease target. In this review we consider the potential application of cell-based therapeutic strategies to disorders of myelin, highlighting the promises as well as the problems and potential perils of this treatment approach.
干细胞生物学的最新进展引发了人们的期望,即中枢神经系统的疾病和损伤都可能通过细胞移植得到改善。特别是,人们已经对细胞疗法进行了研究,以在髓鞘疾病中诱导有效的髓鞘再生,这些疾病包括主要发生在儿童期的髓鞘形成和维持障碍,以及儿童和成人获得性脱髓鞘疾病。针对两大类疾病的潜在细胞疗法包括提供髓鞘生成替代物和动员残余少突胶质细胞祖细胞作为刺激内源性修复的一种手段;然后根据疾病靶点选择治疗方式。在这篇综述中,我们考虑了基于细胞的治疗策略在髓鞘疾病中的潜在应用,强调了这种治疗方法的前景、问题和潜在风险。